Skip to main content
. 2022 Jun 23;127(6):1153–1161. doi: 10.1038/s41416-022-01892-6

Fig. 1. Consort diagram for Phase II randomised controlled clinical trial for vorinostat (VOR)/hydroxychloroquine (HCQ) versus regorafenib (RGF) in refractory metastatic colorectal cancer (mCRC).

Fig. 1

**Crossover is optional and at the discretion of the physician and in the best interest for the patient. po by mouth, C1 Cycle 1.